ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Holdings Decreased by Rubric Capital Management LP

Rubric Capital Management LP reduced its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 90.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,671 shares of the specialty pharmaceutical company's stock after selling 547,129 shares during the period. Rubric Capital Management LP owned about 0.27% of ANI Pharmaceuticals worth $3,381,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new position in shares of ANI Pharmaceuticals in the 1st quarter worth about $106,000. Vanguard Group Inc. lifted its position in shares of ANI Pharmaceuticals by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company's stock worth $90,314,000 after buying an additional 17,460 shares during the last quarter. O Shaughnessy Asset Management LLC bought a new position in shares of ANI Pharmaceuticals in the 1st quarter worth about $218,000. CANADA LIFE ASSURANCE Co lifted its position in shares of ANI Pharmaceuticals by 7.5% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 13,036 shares of the specialty pharmaceutical company's stock worth $900,000 after buying an additional 909 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD bought a new position in shares of ANI Pharmaceuticals in the 1st quarter worth about $289,000. 76.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ANIP shares. Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a research report on Tuesday, October 22nd. HC Wainwright reiterated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Raymond James lifted their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research report on Wednesday, September 18th. Piper Sandler started coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an "overweight" rating and a $68.00 price objective on the stock. Finally, StockNews.com downgraded shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, September 7th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $77.33.

ANI Pharmaceuticals Price Performance

Shares of ANIP stock traded up $1.53 during midday trading on Wednesday, reaching $59.39. 228,701 shares of the company were exchanged, compared to its average volume of 218,832. ANI Pharmaceuticals, Inc. has a 12 month low of $48.20 and a 12 month high of $70.81. The company has a market cap of $1.25 billion, a P/E ratio of -105.20 and a beta of 0.71. The company's 50 day moving average price is $58.32 and its two-hundred day moving average price is $60.76. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping analysts' consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million for the quarter, compared to the consensus estimate of $144.37 million. During the same period in the previous year, the firm earned $1.05 EPS. ANI Pharmaceuticals's revenue was up 12.5% on a year-over-year basis. On average, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.